EJC

National Grid Submits "Future Grid" Plan to Empower Massachusetts' Smarter, Stronger, Cleaner and More Equitable Energy Future

Retrieved on: 
Saturday, September 2, 2023
National Grid plc, EJC, DPU, Plan, Disruptor (video game), Carbon footprint, Electric vehicle, Policy, Electricity, Gasoline, Public, GMAC, Massachusetts Department of Public Utilities, Aircraft, Benefit, Organization, Climate change, National Grid, Investment, Natural gas, Biophysical environment, Climate, Computer, Transport, Weather, Heat, Community engagement, CECP, Renewable energy, Electric power, Commonwealth

WALTHAM, Mass., Sept. 1, 2023 /PRNewswire/ -- National Grid submitted its Electric Sector Modernization Plan (ESMP), the Future Grid Plan, to the Grid Modernization Advisory Council (GMAC) today outlining the critical investments needed in the local electric distribution system over the next five years and beyond to meet the Commonwealth's nation-leading climate change, clean energy, and equity goals as established in the 2050 Clean Energy and Climate Plan (CECP).  As part of National Grid's commitment to delivering a fair, affordable, and clean energy future for all its customers, the Plan outlines a comprehensive and flexible path designed to expand and upgrade the current electric distribution grid, ensure reliability, enable increased electrification, and empower smart customer choices and the transition away from a fossil-based economy.

Key Points: 
  • Today we've submitted a plan that strives to do just that," said Steve Woerner, President, National Grid, New England.
  • We must harness our state's innovative and collaborative spirit to achieve an energy future that works for all."
  • "By developing and submitting this Future Grid Plan as our Electric Sector Modernization Plan, National Grid is taking a critical step towards meeting the energy and climate challenges of today and the future," said Nicola Medalova, National Grid New England's Chief Operating Officer.
  • National Grid will take all feedback and use it to evolve and better inform the formal filing of the Future Grid Plan the company will make to the DPU in January 2024.

Legal Intervention Supports EPA Permit Requirements for St. Croix Refinery

Retrieved on: 
Wednesday, February 15, 2023
Virgin Islands, Accident, Postgraduate education, Motion, Sulfur dioxide, Drinking water, Biophysical environment, Hovensa, ExxonMobil, Sierra Club, LLLP, Hess Corporation, EPA, United States Environmental Protection Agency, Garden, Sierra, Groundwater, Annotation, Safety, Maintenance, United States district court, PDVSA, Vermont Law and Graduate School, Health, Venezuela, Center for Biological Diversity, School, Fear, Biodiversity, Clean Air Act, Congress, HOVENSA, Virgin Islands National Guard, EJC, Limetree, COVID-19, Nausea, PSD, Transport, Public, Circuit court, Fire department, Environment, Policy, Headache, History, Oil, Environmental remediation, Gasoline, Port Hamilton

SOUTH ROYALTON, Vt., Feb. 15, 2023 /PRNewswire-PRWeb/ -- On Monday, Feb. 13, the Environmental Justice Clinic (EJC) at Vermont Law and Graduate School filed a motion to intervene in a case in the United States 3rd Circuit Court of Appeals concerning permits for a shuttered oil refinery in the U.S. Virgin Islands.

Key Points: 
  • The EJC supports the EPA's determination which requires a Prevention of Serious Deterioration (PSD) permit requiring the applicant to install the best available control technology.
  • In May 2021 the EPA used emergency measures to shut down the refinery and reversed its 2018 decision to not require a PSD permit.
  • The EPA is finally taking the risks posed by this facility seriously, and we need to stop the company from starting up that dirty refinery without a new permit."
  • The EPA now considers the refinery a new, stationary source of pollution and as such requires a PSD permit from Port Hamilton.

Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC

Retrieved on: 
Thursday, September 29, 2022
Immunohistochemistry, Safety, HKEX, Metastasis, AR, Disease, CI, Biomarker, EJC, IHC, AST, Survival, Patient, AES, Quality of life, Progression-free survival, Paper, DCR, Death, GT0918, DNA, PIK3CA, PFS, CNV, MBC, Pharmaceutical industry

Recommended phase II dose of pruxelutamide was defined as 200mg orally once daily.

Key Points: 
  • Recommended phase II dose of pruxelutamide was defined as 200mg orally once daily.
  • Pruxelutamide is an oral, newly-generation AR antagonist, developed by Kintor Pharma.
  • In this open-label, dose-expansion, multicentre phase Ib trial, patients with AR+ mBC (immunohistochemistry [IHC] AR1%) received pruxelutamide orally once daily.
  • The data supports further clinical development of pruxelutamide on treating breast cancer patients.

Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment-Published in the European Journal of Cancer

Retrieved on: 
Thursday, May 19, 2022
Immunotherapy, Analyser, CE marking, AI, Bias, Survival, Progression-free survival, Patient, EJC, Workflow, CE, ICI, NSCLC, PD-L1, TPS, European Journal, Decision-making, Large-cell lung carcinoma, Marie Cassidy, CEO, Pharmaceutical industry, Medical device

The study has been published on May 14 in the European Journal of Cancer (EJC).

Key Points: 
  • The study has been published on May 14 in the European Journal of Cancer (EJC).
  • Findings from the study demonstrate the clinical efficacy of Lunit SCOPE PD-L1, the company's AI-powered programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) analyzer, which recently received the CE mark for commercial use in the European market.
  • Last month, Lunit SCOPE PD-L1 TPS received the CE Mark, becoming the first Lunit SCOPE product to receive regulatory approval.
  • Lunit is currently working on launching the AI software in Europe within the second half of 2022.

ReviR Therapeutics Announces Addition of Dr. Lynne E. Maquat and Dr. Brian Safina to Scientific Advisory Board

Retrieved on: 
Friday, May 13, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Senior, RNA transfection, American Academy, Immunology, Research, John J. Carty Award for the Advancement of Science, Voyager, Disease, National, University of Rochester, The arts, Wolf Prize, Biochemistry, Warren Alpert Foundation Prize, EJC, NMD, Association, Therapy, RNA Society, National Academy of Medicine, National academy, Biophysics, Patent, Wolf Prize in Medicine, Fellow of the American Association for the Advancement of Science, RNA, Genentech, University, MicroRNA, American Association, United States Air Force Scientific Advisory Board, Harvard Medical School, University of California, San Diego, Entrepreneurship, Neuroscience, Drug discovery, Pharmaceutical industry, Medical device, Medicine, Science, Science

ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.

Key Points: 
  • ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.
  • We are honored to welcome Dr. Maquat and Dr. Safina to our Scientific Advisory Board, said Peng Yue, Ph.D., Co-Founder, and Chief Executive Officer of ReviR Therapeutics.
  • Each expert will bring in-depth knowledge of RNA biology as well as drug discovery and development expertise.
  • Dr. Maquat brings to ReviR decades of experience in RNA research.

AccuStem’s StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Risk, European Journal of Cancer, European Organisation for Research and Treatment of Cancer, Comparison, European Institute of Oncology, ATAC, European Institute, S, Research, Industry, Breast cancer, Biology, EJC, EORTC, Health, OTC, Regulation, European Journal, Treatment, Woman, European Society for Medical Oncology, Recurrence, Forward-looking statement, Carcinogenesis, Patient, IEO, The Royal Marsden NHS Foundation Trust, Nicola Montani, Epidemiology, SPRS, P, Royal Marsden Hospital, Pharmaceutical industry, Cancer, PHOENIX

Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.

Key Points: 
  • Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.
  • The pivotal TransATAC study has been used to evaluate many of the commonly used breast cancer risk scoring assays, including OncotypeDX, Prosigna, EndoPredict and Breast Cancer Index.
  • In this analysis, investigators demonstrated that patients with a StemPrintER Risk Score (SPRS) Low result had significantly better outcomes than patients with a SPRS High result.
  • Comparison of stemprinter with Oncotype DX recurrence score for predicting risk of breast cancer distant recurrence after endocrine therapy.

511 EJC Wins The Outstanding Building of the Year (TOBY®) Award for 2021

Retrieved on: 
Thursday, December 2, 2021
Mother, Las Colinas, Industry, Tenant, Tree, EJC, Boy Scouts of America National Headquarters, Corporation, Urban area, Work, Building Owners and Managers Association, Mothers Against Drunk Driving, McDonald's, Macdonald, Property management

ADDISON, Texas, Dec. 2, 2021 /PRNewswire/ -- 511 E John Carpenter (EJC)owned by Codina Partners,has been awarded The Outstanding Building of the Year (TOBY) Award, which recognizes quality in commercial buildings and rewards excellence in building management.

Key Points: 
  • ADDISON, Texas, Dec. 2, 2021 /PRNewswire/ -- 511 E John Carpenter (EJC)owned by Codina Partners,has been awarded The Outstanding Building of the Year (TOBY) Award, which recognizes quality in commercial buildings and rewards excellence in building management.
  • "This award reflects an efficient building operating at a level much higher than its peers.
  • 511 East John Carpenter is home to world-class companies like McDonald's Corporation and the National Headquarters for Mothers Against Drunk Driving.
  • 511 EJC is a seven-story office building owned by Codina Partners and managed by Crescent Property Services.